Resignation of Joint Company Secretary

28 July 2023

ASX Code: MXC

LSE Code: MXC

MGC Pharmaceuticals Ltd ("MGC Pharma", "MGC" or the "Company") wishes to advise the Mr Arron Canicais has resigned as Joint Company Secretary effective today, with Mr Rowan Harland remaining as sole Company Secretary. The Company would like to thank Mr Canicais for his contributions to the Company and wishes him the very best for the next stage of his career.

Mr Harland will be responsible for communication with the ASX in relation to listing rule matters, pursuant to Listing Rule 12.6.

-Ends-

Authorised for release by the board of directors, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma